Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. - Wikidata - wikimedia - TriplyDB

Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

http://www.wikidata.org/entity/Q35003408

about

HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls Defining cognitive impairment in people-living-with-HIV: the POPPY study.Cerebrospinal fluid (CSF) biomarkers of iron status are associated with CSF viral load, antiretroviral therapy, and demographic factors in HIV-infected adults.Opinion: Inhibition of Blood-Brain Barrier Repair as a Mechanism in HIV-1 Disease.Cognitive Decline in Relation to Psychological Wellbeing and HIV Disease- and Treatment Characteristics in HIV-Infected Patients on cART: A One-Year Follow-Up Study.MicroRNAs upregulated during HIV infection target peroxisome biogenesis factors: Implications for virus biology, disease mechanisms and neuropathology Burden of sleep disturbances and associated risk factors: A cross-sectional survey among HIV-infected persons on antiretroviral therapy across China.Aging with HIV-1 Infection: Motor Functions, Cognition, and Attention--A Comparison with Parkinson's Disease The effects of antiretroviral treatment initiation on cognition in HIV-infected individuals with advanced disease in Pune, India.The Effect of Central Nervous System Penetration Effectiveness of Highly Active Antiretroviral Therapy on Neuropsychological Performance and Neuroimaging in HIV Infected Individuals Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.Characteristics of Resting-State Functional Connectivity in HIV-Associated Neurocognitive Disorder Identifying Neurocognitive Decline at 36 Months among HIV-Positive Participants in the CHARTER Cohort Using Group-Based Trajectory Analysis.Increased Intrathecal Immune Activation in Virally Suppressed HIV-1 Infected Patients with Neurocognitive Impairment Does Older Age Confer an Increased Risk of Incident Neurocognitive Disorders Among Persons Living with HIV Disease?Mitochondrial DNA Haplogroups and Neurocognitive Impairment During HIV Infection.Cognitive change trajectories in virally suppressed HIV-infected individuals indicate high prevalence of disease activity Reading Ability as an Estimator of Premorbid Intelligence: Does It Remain Stable Among Ethnically Diverse HIV+ Adults?Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study Anemia and Red Blood Cell Indices Predict HIV-Associated Neurocognitive Impairment in the Highly Active Antiretroviral Therapy Era Lower CSF Aβ is Associated with HAND in HIV-Infected Adults with a Family History of Dementia Macrophages in Progressive Human Immunodeficiency Virus/Simian Immunodeficiency Virus Infections.European Mitochondrial DNA Haplogroups are Associated with Cerebrospinal Fluid Biomarkers of Inflammation in HIV Infection.Neuronal Stress and Injury Caused by HIV-1, cART and Drug Abuse: Converging Contributions to HAND.Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment.Chronic low-level expression of HIV-1 Tat promotes a neurodegenerative phenotype with aging.A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes.Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS.Monitoring HIV-Associated Neurocognitive Disorder Using Screenings: a Critical Review Including Guidelines for Clinical and Research Use.HIV, Tat and dopamine transmission.Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study.Proton Chemical Shift Imaging Study of the Combined Antiretroviral Therapy Impact on Neurometabolic Parameters in Chronic HIV Infection.Cognitive Impairment and Persistent CNS Injury in Treated HIV.Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Predictors and Impact of Self-Reported Suboptimal Effort on Estimates of Prevalence of HIV-Associated Neurocognitive Disorders.Treating HIV Infection in the Central Nervous System.Improving Detection of HIV-Associated Cognitive Impairment: Comparison of the International HIV Dementia Scale and a Brief Screening Battery.Effort and neuropsychological performance in HIV-infected individuals on stable combination antiretroviral therapy.

P2860

Q26766448-B3F1CC6E-EE8D-44F3-9F90-7B2F9194B37D Q28066725-78BC8409-9D0E-4713-826B-902153EE41F1 Q30250271-D0080CAD-DED3-462A-AEC1-79E19E13F544 Q30826784-522A3127-DA70-4657-AD68-024E1A553D0A Q33587212-F8F94E45-030D-4614-8427-F13E195B8C16 Q33603457-53135C4B-4615-41F5-A13E-02DB03CF5E6C Q33650273-5B8D69B5-667B-4094-8FE1-208391FAEC9C Q33778861-B7573E94-CA3D-428A-822C-57B762333316 Q33807989-F8BB2CFE-F912-40D8-9E8B-161A8B859866 Q33920647-6EF0EB31-66CD-4813-95DF-89C29B19D11F Q35883236-89737F6E-0537-440E-8968-C38CDED0A43D Q35987635-D9A325BE-7A61-444F-9C6D-FD9EC64819B3 Q35996619-E3C4E42C-95A1-49FA-9457-5BD64CABE428 Q35996770-487F2C9D-CB42-4ADF-873C-ACCECBBEA6C9 Q36020991-31F3BDD8-739E-4E93-9654-075F7A68364C Q36050420-E4780E57-1D84-4219-8AD4-92D00C411FBA Q36060119-E11B8A97-2BF6-4484-861C-306D7092958D Q36141245-E9007848-45F5-4342-A1F3-20FE09CD0841 Q36298436-B2AA0469-DB6C-4FF7-AE45-B577A92BA3BE Q36535257-E9A63D30-A718-4F78-A1F6-D2C257AAAEA5 Q36645145-42A7FEA6-5DA3-4742-BB73-5E122133824C Q36654580-8239165B-A676-44C9-8E1F-A81020DC3661 Q37026506-C41E448B-0157-436B-9B6A-3FC8D943E40C Q37182704-AFBF2BCC-B69D-455A-9AFA-BBE244C91FB3 Q37701959-5AD96EAB-6863-4B67-896A-509F7A235780 Q37721505-3BDBFF38-53F6-4FB9-9F27-590F33ACB60C Q37731654-C451F0A3-D404-4D64-BEE6-0F38EB414AD1 Q38629705-C37A8CCC-3DCD-4FF3-B8DC-EF1F1A84B98A Q38654059-3AD8CAC8-2F15-4D4A-A4ED-E051F6EB5792 Q38687781-B7BF2668-7C99-4DAE-877E-78E1B8A0E6F9 Q38747341-F211662E-9F65-4804-9A32-2C6414BD4783 Q38812005-C1E3A2DC-1430-497A-8E88-1ABDC5257CFB Q38817668-D8BB0956-B693-4ABC-A1D0-B8C7A6D661C1 Q38827785-6BA323E5-C647-4ED9-B6CC-4AB406E40C9D Q38836472-370160DA-88A6-40C2-BD46-62094426FBF3 Q38882614-F5A9D63D-88C4-4540-A435-45F2F76F684F Q38886999-EE5CB515-8DDB-4742-A9D0-12667E60AE1B Q39077816-0BAA39F8-A07D-48DF-BA48-7AC4562DBE3D Q39201495-82AC6E8C-8376-438A-9492-29BA9D6E18D3 Q40046051-AA2FA59D-CD40-45B3-A382-A74323D46A32

P2860

Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study.

http://www.wikidata.org/entity/Q35003408

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Neurocognitive change in the e ...... he longitudinal CHARTER study.

@ast

Neurocognitive change in the e ...... he longitudinal CHARTER study.

@en

type

label

Neurocognitive change in the e ...... he longitudinal CHARTER study.

@ast

Neurocognitive change in the e ...... he longitudinal CHARTER study.

@en

prefLabel

Neurocognitive change in the e ...... he longitudinal CHARTER study.

@ast

Neurocognitive change in the e ...... he longitudinal CHARTER study.

@en

P1433

Q35003408-28B9EA2A-6CE4-4C18-97AD-1B1FB9DE5DAC

P1476

Q35003408-33B872B9-9B21-42F0-9527-B9303B0B5E4B

P2093

Q35003408-12EDB3AF-36BD-4AF2-B7B9-9BE0391B111E

Q35003408-246DD801-75D3-4398-83EB-813612C2172B

Q35003408-420149BD-58E6-4D00-9ADA-C65AA76B785F

Q35003408-4E6B4167-F87B-46D0-BCF2-B6326553966C

Q35003408-60B32C96-037D-4761-A0AE-06DDCC1C58DE

Q35003408-6C111D98-A03E-40B8-B418-7F9B715BDD9C

Q35003408-7CAEFAC1-7BDF-4A4A-A052-0C103EEC4DD9

Q35003408-9D84DC1E-B3D2-48DD-96A2-86A9AADFC9BE

Q35003408-A0BDE04D-8A04-4415-A079-BF14447161D3

Q35003408-A1B74E11-10E2-4499-A644-C599720F4982

P2860

Q35003408-07662901-11AF-4A3B-9615-9AEFE0B94F7C

Q35003408-0D132F60-C972-4B1B-B1DA-0182C613ABDA

Q35003408-14FCBA5F-76B7-4D7B-8B4A-883260794F10

Q35003408-15AC11E6-8F42-4089-8F65-02809D81DDA5

Q35003408-21367E87-EA70-4223-AD15-1C4537D6CFC7

Q35003408-2B3D9FD0-12CA-4249-BF6C-4745D4674BB9

Q35003408-2D24A1A3-1EBC-4D2B-8538-22F105830C45

Q35003408-635E8435-4FBE-4227-9034-E8FB56ED9329

Q35003408-88ABD33C-DBA9-460D-9BEF-0D737B5F4FB7

Q35003408-95E8A1E6-E9DE-421D-91C0-1C1B3ADCA763

P304

Q35003408-FD040CA0-E29C-421E-8795-953FAB558897

P31

Q35003408-C4BB6438-4BF3-4F98-ABA7-DBB775586DD0

P356

Q35003408-468E9CF2-3641-4FC9-9FBE-0C13DF75C9B8

P407

Q35003408-720E614A-BCE5-44EB-AFD3-F2783A494E7E

P433

Q35003408-115B0385-A278-4DFE-B007-A2A7E9019C08

P478

Q35003408-03FA32C9-9801-4747-AD64-31D3F2B5572E

P50

Q35003408-2C854BFE-A163-4E14-A0E0-CA62545DFE4B

Q35003408-33079EFD-F4E9-4BA7-9B34-0A5371538FED

Q35003408-4EDDD65E-EA2F-4D03-908A-F9B33B8AB118

Q35003408-611BC01E-A2C9-4A77-B548-6A5C64B5B927

Q35003408-7331C794-C792-400C-9A22-6736B5BE2C29

Q35003408-7F85E665-74D2-4054-934E-F70A37E4AD4D

Q35003408-912675CA-E4BC-4BC3-ADB7-5D244EEDF92A

Q35003408-DAC5EDC2-295C-4E9C-8964-0141E5CC7F1A

P577

Q35003408-AC4FD815-EEAB-4500-9733-FD4F1915D25D

P5875

Q35003408-28ACC990-47A8-4A6E-8367-8B9633D4B6D0

P698

Q35003408-608434CD-56B9-4C60-B167-B28B29A56D5C

P921

Q35003408-37A28306-D275-4432-A968-CF4F2B84D444

P932

Q35003408-1F3730AF-1FEB-42BA-AD36-DFA357A2FCA3

P356

P1433

Clinical Infectious Diseases

P1476

Neurocognitive change in the e ...... he longitudinal CHARTER study.

@en

P2093

Ann C Collier

http://www.w3.org/2001/XMLSchema#string

Anthony C Gamst

http://www.w3.org/2001/XMLSchema#string

Benjamin B Gelman

http://www.w3.org/2001/XMLSchema#string

Christina M Marra

http://www.w3.org/2001/XMLSchema#string

David B Clifford

http://www.w3.org/2001/XMLSchema#string

David M Simpson

http://www.w3.org/2001/XMLSchema#string

David M Smith

http://www.w3.org/2001/XMLSchema#string

Donald R Franklin

http://www.w3.org/2001/XMLSchema#string

Florin Vaida

http://www.w3.org/2001/XMLSchema#string

Ian Abramson

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors

Cognitive reserve.

Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change.

Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China

Disparities in outcomes for African American and Latino subjects in the Flexible Initial Retrovirus Suppressive Therapies (FIRST) trial.

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

Late entry to HIV care among Latinos compared with non-Latinos in a southeastern US cohort.

Updated research nosology for HIV-associated neurocognitive disorders

A systematic review of HIV/AIDS survival and delayed diagnosis among Hispanics in the United States.

Lower cognitive reserve among individuals with syndromic HIV-associated neurocognitive disorders (HAND).

P304

473-480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIU862

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Christine Fennema-Notestine

Robert K Heaton

Steven Paul Woods

P577

2014-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

267745609

http://www.w3.org/2001/XMLSchema#string

P698

25362201

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

4303775

http://www.w3.org/2001/XMLSchema#string